Integrin α1/β1 and α2/β1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy.
IgA nephropathy (IgAN) is characterized by mesangial deposition of IgA1 and galactose-deficient IgA1 is expected to play a pathogenic role. However, the identity of the receptor for IgA1 is still controversial. Hence, the aim of this study was to explore the receptor for galactose-deficient IgA1. Human monoclonal IgA1 was treated with exoglycosidase and FITC-conjugated control, asialo- and agalactosyl-IgA1 was used as a probe to detect the receptor in cultured human mesangial cells. Tumor necrosis factor-α or transforming growth factor-β1 treatment accelerated IgA1-binding on mesangial cells, and these effects were diminished by the addition of dexamethasone, whereas these changes were not dependent on galactose-deficiency of IgA1. According to comprehensive gene expression analysis, we focused on integrin β1. Pre-treatment by Mn(2+), which activates integrin by changing its structure, enhanced the binding of IgA1 in cultured mesangial cells. Furthermore, pre-incubation with collagens specifically enhanced binding of IgA1 in the cultured human mesangial cells without activation by Mn(2+). Collagen type IV distributed in the mesangial region of the glomeruli as well as Bowman's capsule and tubular basal membrane in IgAN patients, and the IgA1 with collagen type IV induced proliferative signals on mesangial cells by phosphorylating extracellular signal-regulated kinase more effectively than the IgA1 alone. Immunoprecipitation assay revealed the binding of IgA1 and integrin α1/β1 and α2/β1 heterodimer and down-regulation of integrin α1, α2 and β1 expression in human mesangial cells induced by each specific small interfering RNA diminished the ability to bind IgA1 probe. Integrin α1/β1 and α2/β1 would be a candidate receptor for IgA1.
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 9518510, Japan. kanekoy@med.niigata-u.ac.jp
Yoshikatsu
Y
Kaneko
Tadashi
T
Otsuka
Yohei
Y
Tsuchida
Fumitake
F
Gejyo
Ichiei
I
Narita
D002478:Cells, Cultured; D024141:Collagen Type IV / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D016650:Fluorescein-5-isothiocyanate / Q000494:pharmacology; D005920:Glomerular Mesangium / Q000276:immunology* / Q000378:metabolism; D005922:Glomerulonephritis, IGA / Q000276:immunology* / Q000378:metabolism; D006026:Glycoside Hydrolases / Q000378:metabolism; D006801:Humans; D007070:Immunoglobulin A / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D039222:Integrin alpha1beta1 / Q000378:metabolism*; D038982:Integrin alpha2beta1 / Q000378:metabolism*; D008345:Manganese / Q000494:pharmacology; D050527:Mesangial Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D055503:Protein Multimerization; D034622:RNA Interference; D034741:RNA, Small Interfering; D015291:Transforming Growth Factors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D024141:Collagen Type IV; D007070:Immunoglobulin A; D039222:Integrin alpha1beta1; D038982:Integrin alpha2beta1; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; D008345:Manganese; D015291:Transforming Growth Factors; D003907:Dexamethasone; D006026:Glycoside Hydrolases; D016650:Fluorescein-5-isothiocyanate